Biocon reports Q2 FY25 net loss at Rs. 16 Cr
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
Silica is a proven and highly effective anti-caking agent that has been used for decades
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
Subscribe To Our Newsletter & Stay Updated